These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9552042)

  • 1. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
    Sculier JP; Paesmans M; Thiriaux J; Lecomte J; Bureau G; Giner V; Efremidis A; Lafitte JJ; Berchier MC; Alexopoulos CG; Zacharias C; Mommen P; Ninane V; Klastersky J
    J Clin Oncol; 1998 Apr; 16(4):1388-96. PubMed ID: 9552042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
    Sculier JP; Klastersky J; Giner V; Bureau G; Thiriaux J; Dabouis G; Efremidis A; Ries F; Berchier MC; Sergysels R
    J Clin Oncol; 1994 Feb; 12(2):353-9. PubMed ID: 8113843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Lecomte J; Berghmans T; Thiriaux J; Florin MC; Efremidis A; Alexopoulos CG; Recloux P; Ninane V; Mommen P; Paesmans M; Klastersky J;
    Ann Oncol; 2002 Jun; 13(6):874-82. PubMed ID: 12123332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
    Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
    Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.
    Ahn JB; Ko WK; Lee JG; Shim KY; Jeung HC; Park JO; Yoo NC; Kim BS; Kim SK; Kim SK; Kim JH
    Am J Clin Oncol; 2000 Dec; 23(6):622-8. PubMed ID: 11202811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX; Chen XB
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
    Booton R; Lorigan P; Anderson H; Baka S; Ashcroft L; Nicolson M; O'Brien M; Dunlop D; O'Byrne K; Laurence V; Snee M; Dark G; Thatcher N
    Ann Oncol; 2006 Jul; 17(7):1111-9. PubMed ID: 16603599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Berghmans T; Van Houtte P; Lecomte J; Thiriaux J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Paesmans M; Mommen P; Ninane V;
    Ann Oncol; 2004 Mar; 15(3):399-409. PubMed ID: 14998841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
    J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
    Crinò L; Scagliotti GV; Ricci S; De Marinis F; Rinaldi M; Gridelli C; Ceribelli A; Bianco R; Marangolo M; Di Costanzo F; Sassi M; Barni S; Ravaioli A; Adamo V; Portalone L; Cruciani G; Masotti A; Ferrara G; Gozzelino F; Tonato M
    J Clin Oncol; 1999 Nov; 17(11):3522-30. PubMed ID: 10550150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
    Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
    Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party.
    Sculier JP; Paesmans M; Lafitte JJ; Baumöhl J; Thiriaux J; van Cutsem O; Recloux P; Bureau G; Berchier MC; Zacharias C; Mommen P; Bosschaerts T; Berghmans T; van Houtte P; Ninane V; Klastersky J
    Ann Oncol; 1999 Mar; 10(3):295-303. PubMed ID: 10355573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC).
    Preti P; Poggi G; Cuomo AM; Robustelli della Cuna FS; Zambelli A; Pavesi L
    J Chemother; 1998 Dec; 10(6):492-5. PubMed ID: 9876059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
    Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
    J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.
    Sculier JP; Paesmans M; Thiriaux J; Lecomte J; Bureau G; Giner V; Koumakis G; Lafitte JJ; Berchier MC; Alexopoulos CG; Zacharias C; Mommen P; Ninane V; Klastersky J
    Eur J Cancer; 1999 Sep; 35(9):1314-9. PubMed ID: 10658520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.